General Info

Inovio Biomedical Corporation is a late-stage biomedical company focused on commercializing its proprietary selective electrochemical tumor ablation therapy. SECTA targets a significant unmet clinical need: the local treatment of solid tumors with selective killing of cancer cells while preserving healthy tissue. Inovio is moving its lead product, the MedPulser, through premarketing studies for head and neck cancer and skin cancers in Europe where it has CE Mark accreditation. Merck, Vical, University of Southampton and H. Lee Moffitt Cancer Center are using Inovio's gene-delivery technology in clinical studies of novel DNA therapeutics delivered using electroporation. Inovio is one of the leaders in developing human therapeutic applications of electroporation, with the industry's most extensive patent portfolio covering in vivo electroporation. The company trades on the American Stock Exchange under the symbol INO. It is headquartered in San Diego.